These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28678431)

  • 1. Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis.
    Sakuma Y
    Pathol Int; 2017 Aug; 67(8):379-388. PubMed ID: 28678431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tannic acid attenuates TGF-β1-induced epithelial-to-mesenchymal transition by effectively intervening TGF-β signaling in lung epithelial cells.
    Pattarayan D; Sivanantham A; Krishnaswami V; Loganathan L; Palanichamy R; Natesan S; Muthusamy K; Rajasekaran S
    J Cell Physiol; 2018 Mar; 233(3):2513-2525. PubMed ID: 28771711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.
    Xu S; Liu X; Liu R; Shi T; Li X; Zhong D; Wang Y; Chen G; Chen J
    Thorac Cancer; 2017 Nov; 8(6):693-697. PubMed ID: 28786540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblastic foci, covered with alveolar epithelia exhibiting epithelial-mesenchymal transition, destroy alveolar septa by disrupting blood flow in idiopathic pulmonary fibrosis.
    Yamaguchi M; Hirai S; Tanaka Y; Sumi T; Miyajima M; Mishina T; Yamada G; Otsuka M; Hasegawa T; Kojima T; Niki T; Watanabe A; Takahashi H; Sakuma Y
    Lab Invest; 2017 Mar; 97(3):232-242. PubMed ID: 27941755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma.
    Yamaguchi M; Hirai S; Sumi T; Tanaka Y; Tada M; Nishii Y; Hasegawa T; Uchida H; Yamada G; Watanabe A; Takahashi H; Sakuma Y
    Biochem Biophys Res Commun; 2017 Jun; 487(3):613-618. PubMed ID: 28433633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer.
    Bronte G; Bravaccini S; Bronte E; Burgio MA; Rolfo C; Delmonte A; Crinò L
    Biol Rev Camb Philos Soc; 2018 Nov; 93(4):1735-1746. PubMed ID: 29671943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
    Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
    Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
    Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition.
    Hwang W; Chiu YF; Kuo MH; Lee KL; Lee AC; Yu CC; Chang JL; Huang WC; Hsiao SH; Lin SE; Chou YT
    Cancer Res; 2017 Jun; 77(11):3013-3026. PubMed ID: 28381546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL9 Regulates TGF-β1-Induced Epithelial to Mesenchymal Transition in Human Alveolar Epithelial Cells.
    O'Beirne SL; Walsh SM; Fabre A; Reviriego C; Worrell JC; Counihan IP; Lumsden RV; Cramton-Barnes J; Belperio JA; Donnelly SC; Boylan D; Marchal-Sommé J; Kane R; Keane MP
    J Immunol; 2015 Sep; 195(6):2788-96. PubMed ID: 26268659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.
    Kurimoto R; Iwasawa S; Ebata T; Ishiwata T; Sekine I; Tada Y; Tatsumi K; Koide S; Iwama A; Takiguchi Y
    Int J Oncol; 2016 May; 48(5):1825-36. PubMed ID: 26984042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
    Xie M; Zhang L; He CS; Xu F; Liu JL; Hu ZH; Zhao LP; Tian Y
    J Cell Biochem; 2012 May; 113(5):1501-13. PubMed ID: 22173954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.
    Tulchinsky E; Demidov O; Kriajevska M; Barlev NA; Imyanitov E
    Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):29-39. PubMed ID: 30419315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of permeability alteration and epithelial-mesenchymal transition induced by transforming growth factor-β
    Togami K; Yamaguchi K; Chono S; Tada H
    J Pharmacol Toxicol Methods; 2017 Jul; 86():19-27. PubMed ID: 28259823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells.
    Sakuma Y; Yamazaki Y; Nakamura Y; Yoshihara M; Matsukuma S; Koizume S; Miyagi Y
    Biochem Biophys Res Commun; 2012 Jul; 423(4):667-71. PubMed ID: 22695117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.